<p>Zhengxian Gu and colleagues at PTC Therapeutics, Inc. in the U.S. will investigate the mechanism of action used by a class of small molecules shown to specifically activate HIV. Understanding the pathways for reactivation of latent HIV could inform development of drug therapies to eliminate latent HIV reservoirs and effectively cure HIV.</p>


Zhengxian Gu and colleagues at PTC Therapeutics, Inc. in the U.S. will investigate the mechanism of action used by a class of small molecules shown to specifically activate HIV. Understanding the pathways for reactivation of latent HIV could inform development of drug therapies to eliminate latent HIV reservoirs and effectively cure HIV.